Total Payments
$18,952
2024 Payments
$696.86
Companies
17
Transactions
192
Medicare Patients
1,626
Medicare Billing
$1.2M
Payment Breakdown by Category
Research$14,906 (78.7%)
Food & Beverage$3,359 (17.7%)
Travel$674.07 (3.6%)
Education$13.60 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,906 | 10 | 78.7% |
| Food and Beverage | $3,359 | 179 | 17.7% |
| Travel and Lodging | $674.07 | 2 | 3.6% |
| Education | $13.60 | 1 | 0.1% |
Payments by Type
Research
$14,906
10 transactions
General
$4,046
182 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Dynavax Technologies Corporation | $13,625 | 9 | $0 (2022) |
| Amgen Inc. | $2,136 | 37 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $1,380 | 107 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $874.12 | 3 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $380.17 | 11 | $0 (2024) |
| Ardelyx, Inc. | $200.43 | 8 | $0 (2024) |
| Vifor Pharma, Inc. | $74.45 | 3 | $0 (2022) |
| OPKO Pharmaceuticals, LLC | $56.72 | 3 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $46.52 | 2 | $0 (2022) |
| Galt Pharmaceuticals, LLC | $37.34 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $696.86 | 31 | Ardelyx, Inc. ($200.43) |
| 2023 | $590.28 | 22 | Fresenius USA Marketing, Inc. ($256.33) |
| 2022 | $4,037 | 30 | Dynavax Technologies Corporation ($3,500) |
| 2021 | $436.94 | 36 | Fresenius USA Marketing, Inc. ($364.32) |
| 2020 | $444.88 | 35 | Fresenius USA Marketing, Inc. ($220.81) |
| 2019 | $1,293 | 30 | Dynavax Technologies Corporation ($875.00) |
| 2018 | $10,580 | 5 | Dynavax Technologies Corporation ($9,250) |
| 2017 | $874.12 | 3 | BOSTON SCIENTIFIC CORPORATION ($874.12) |
All Payment Transactions
192 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $33.56 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/02/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/11/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Diabetes | ||||||
| 10/04/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Nephrology | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/17/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/16/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: Phosphate binder for ESRD | ||||||
| 08/07/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/20/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/12/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: NEPHROLOGY | ||||||
| 06/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/17/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv | Food and Beverage | In-kind items and services | $33.49 | General |
| Category: Nephrology | ||||||
| 05/07/2024 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $36.72 | General |
| Category: Nephrology | ||||||
| 05/04/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $31.24 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/26/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Phosphate binder for ESRD | ||||||
| 04/25/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Phosphate binder for ESRD | ||||||
| 04/25/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $0.57 | General |
| Category: Phosphate binder for ESRD | ||||||
| 04/12/2024 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $30.73 | General |
| Category: Nephrology | ||||||
| 03/13/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Phosphate binder for ESRD | ||||||
| 03/12/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Phosphate binder for ESRD | ||||||
| 03/12/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $3.23 | General |
| Category: Phosphate binder for ESRD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis | Dynavax Technologies Corporation | $13,625 | 9 |
| OLE 2 | Amgen Inc. | $1,281 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 361 | 1,310 | $496,059 | $262,565 |
| 2022 | 6 | 331 | 1,198 | $537,737 | $260,276 |
| 2021 | 7 | 378 | 1,501 | $626,727 | $311,890 |
| 2020 | 8 | 556 | 2,144 | $632,483 | $358,594 |
Total Patients
1,626
Total Services
6,153
Medicare Billing
$1.2M
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 114 | 679 | $352,401 | $185,567 | 52.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 86 | 186 | $80,352 | $43,277 | 53.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 68 | 284 | $32,602 | $17,865 | 54.8% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 28 | 34 | $10,166 | $5,326 | 52.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 49 | $8,526 | $4,640 | 54.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 52 | $7,072 | $3,201 | 45.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 26 | $4,940 | $2,688 | 54.4% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 100 | 655 | $382,779 | $186,353 | 48.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 89 | 222 | $107,617 | $51,510 | 47.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 74 | 215 | $24,725 | $12,303 | 49.8% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 24 | 32 | $10,688 | $5,030 | 47.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 62 | $9,312 | $3,789 | 40.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $2,616 | $1,291 | 49.4% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 105 | 777 | $454,739 | $226,428 | 49.8% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 84 | 204 | $99,264 | $48,736 | 49.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 94 | 358 | $41,170 | $20,907 | 50.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 28 | 67 | $10,128 | $4,972 | 49.1% |
| 90962 | Dialysis services (1 physician visit per month), patient 20 years of age and older | Office | 2021 | 21 | 25 | $8,350 | $4,230 | 50.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 42 | $6,972 | $3,525 | 50.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 27 | 28 | $6,104 | $3,091 | 50.6% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 141 | 961 | $408,425 | $226,816 | 55.5% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2020 | 135 | 375 | $132,195 | $74,445 | 56.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 140 | 597 | $58,239 | $35,959 | 61.7% |
| 90962 | Dialysis services (1 physician visit per month), patient 20 years of age and older | Office | 2020 | 50 | 61 | $14,701 | $9,512 | 64.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 61 | $8,452 | $5,293 | 62.6% |
About Dr. Mark Lee, MD
Dr. Mark Lee, MD is a Internal Medicine healthcare provider based in Whittier, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558322479.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Lee, MD has received a total of $18,952 in payments from pharmaceutical and medical device companies, with $696.86 received in 2024. These payments were reported across 192 transactions from 17 companies. The most common payment nature is "" ($14,906).
As a Medicare-enrolled provider, Lee has provided services to 1,626 Medicare beneficiaries, totaling 6,153 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Whittier, CA
- Active Since 03/30/2006
- Last Updated 07/20/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558322479
Products in Payments
- Heplisav-B (Drug) $13,625
- Parsabiv (Biological) $1,576
- Velphoro (Drug) $1,374
- GENERAL - THERAPIES (Device) $874.12
- Parsabiv (Drug) $503.45
- LOKELMA (Drug) $380.17
- IBSRELA (Drug) $200.43
- RAYALDEE (Drug) $56.72
- Aranesp (Biological) $56.47
- Veltassa (Drug) $55.63
- LUPKYNIS (Drug) $46.52
- Korsuva (Drug) $41.67
- Orphengesic Forte (Drug) $37.34
- AURYXIA (Drug) $30.82
- JARDIANCE (Drug) $21.76
- OPSUMIT MACITENTAN (Drug) $20.47
- Kerendia (Drug) $16.02
- JYNARQUE (Drug) $15.41
- TARPEYO (Drug) $13.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Whittier
Jayakumar Vidhun, M.d, M.D
Internal Medicine — Payments: $413,543
Internal Medicine $413,543
Tien I Su, M.d, M.D
Internal Medicine — Payments: $144,568
Internal Medicine $144,568
Walter Le
Internal Medicine — Payments: $40,972
Internal Medicine $40,972
Dr. Juan Montes, M.d, M.D
Internal Medicine — Payments: $10,928
Internal Medicine $10,928
Kesheng Wu, Md, MD
Internal Medicine — Payments: $5,355
Internal Medicine $5,355
Kevin Huang, M.d, M.D
Internal Medicine — Payments: $4,437
Internal Medicine $4,437